



The Effects of Prostaglandin E₂ Treatment on the Secretory Function of Mare Corpus Luteum Depends on the Site of Application: An *in vivo* Study

OPEN ACCESS

Edited by:

Margherita Maranesi,
University of Perugia, Italy

Reviewed by:

Cecilia Dall'Aglio,
University of Perugia, Italy
Massimo Zerani,
University of Perugia, Italy

*Correspondence:

Dariusz J. Skarzynski
d.skarzynski@pan.olsztyn.pl

†ORCID:

Katarzyna K. Piotrowska-Tomala
orcid.org/0000-0001-6989-9243

Agnieszka W. Jonczyk
orcid.org/0000-0002-6867-0823

Anna Z. Szóstek-Mioduchowska
orcid.org/0000-0003-4204-1698

Graca Ferreira-Dias
orcid.org/0000-0003-0622-6513

Dariusz J. Skarzynski
orcid.org/0000-0001-9537-3560

Specialty section:

This article was submitted to
Animal Reproduction -
Theriogenology,
a section of the journal
Frontiers in Veterinary Science

Received: 05 August 2021

Accepted: 28 December 2021

Published: 15 February 2022

Citation:

Piotrowska-Tomala KK, Jonczyk AW,
Szóstek-Mioduchowska AZ,
Żebrowska E, Ferreira-Dias G and
Skarzynski DJ (2022) The Effects of
Prostaglandin E₂ Treatment on the
Secretory Function of Mare Corpus
Luteum Depends on the Site of
Application: An *in vivo* Study.
Front. Vet. Sci. 8:753796.
doi: 10.3389/fvets.2021.753796

Katarzyna K. Piotrowska-Tomala^{1†}, Agnieszka W. Jonczyk^{1†},
Anna Z. Szóstek-Mioduchowska^{1†}, Ewelina Żebrowska¹, Graca Ferreira-Dias^{2†} and
Dariusz J. Skarzynski^{1*†}

¹ Department Reproductive Immunology and Pathology, Institute of Animal Reproduction and Food Research, Polish Academy of Sciences, Olsztyn, Poland, ² Faculty of Veterinary Medicine, CIISA - Centre for Interdisciplinary Research in Animal Health, University of Lisbon, Lisbon, Portugal

We examined the effect of prostaglandin (PG) E₂ on the secretory function of equine corpus luteum (CL), according to the application site: intra-CL injection vs. an intrauterine (intra-U) administration. Moreover, the effect of intra-CL injection vs. intra-U administration of both luteotropic factors: PGE₂ and human chorionic gonadotropin (hCG) as a positive control, on CL function was additionally compared. Mares were assigned to the groups ($n = 6$ per group): (1) an intra-CL saline injection (control); (2) an intra-CL injection of PGE₂ (5 mg/ml); (3) an intra-CL injection of hCG (1,500 IU/ml); (4) an intra-U saline administration (control); (5) an intra-U administration of PGE₂ (5 mg/5 ml); (6) an intra-U administration of hCG (1,500 IU/5 ml). Progesterone (P₄) and PGE₂ concentrations were measured in blood plasma samples collected at -2 , -1 , and 0 (pre-treatment), and at 1, 2, 3, 4, 6, 8, 10, 12, and 24 h after treatments. Moreover, effects of different doses of PGE₂ application on the concentration of total PGF_{2 α} (PGF_{2 α} and its main metabolite 13,14-dihydro-15-keto-prostaglandin F_{2 α} - PGFM) was determined. The time point of PGE₂, hCG, or saline administration was defined as hour "0" of the experiment. An intra-CL injection of PGE₂ increased P₄ and PGE₂ concentrations between 3 and 4 h or at 3 and 12 h, respectively ($p < 0.05$). While intra-U administration of PGE₂ elevated P₄ concentrations between 8 and 24 h, PGE₂ was upregulated at 1 h and between 3 and 4 h ($p < 0.05$). An intra-CL injection of hCG increased P₄ concentrations at 1, 6, and 12 h ($p < 0.05$), while its intra-U administration enhanced P₄ and PGE₂ concentrations between 1 and 12 h or at 3 h and between 6 and 10 h, respectively ($p < 0.05$). An application of PGE₂, dependently on the dose, supports equine CL function, regardless of the application site, consequently leading to differences in both P₄ and PGE₂ concentrations in blood plasma.

Keywords: prostaglandin E₂, human chorion gonadotropin, corpus luteum, progesterone, mare

INTRODUCTION

Corpus luteum (CL) is critical for reproductive cyclicity and pregnancy maintenance, which depends on the supportive action of progesterone (P₄) secreted by this transient endocrine gland (1–3). The lifespan of CL is controlled by numerous regulatory factors with luteotropic and luteolytic effects (4) such as cytokines, growth factors, P₄, 17β-estradiol (E₂), luteinizing hormone (LH), prostaglandin (PG) E₂, and PGF_{2α}, respectively (5–7). Some of these factors are widely applied in veterinary practice for estrus synchronization. Mostly, PGF_{2α} is used for the regulation of the estrous cycles in the mare. However, application of PGE₂ or LH analogs (human chorionic gonadotropin; hCG and equine chorionic gonadotropin; eCG) are also key areas of veterinarian interests in the control of equine reproduction. In addition, the interesting issues in the veterinary practice are different models of drug administration have been investigated in farm animals (5, 8, 9).

Human chorionic gonadotropin is a glycoprotein purified from the urine of pregnant women (10). This glycoprotein acts as LH, sharing the same receptor (1). The evidence for the presence of the LH/CGR receptor in the reproductive tract of humans and other domestic animals has been previously described (11, 12). Moreover, in mares, the LH receptor is expressed in the endometrium and myometrium during the estrous cycle and anestrus (13). Intramuscular (i.m.) (14), subcutaneous (s.c.) (10), or intravenous (i.v.) (15–17) hCG administration has shown a good efficacy in the induction of ovulation to improve the time of mating in mares. Moreover, in mares at early diestrus, i.m. (18) or i.v. (19) hCG application results in an increase in circulating progestin concentrations. Other studies using hCG found promising results in breeding mares. Intravenous hCG administration has been advocated for use to increase fertility and early equine pregnancy rates (20). In addition, the positive effect of i.v. or i.m. hCG administration on an additional CL formation and an increase in pregnancy rates have been reported in cattle (21–24). Therefore, in our study hCG was used as a control-reference luteotropic factor.

Prostaglandins are key factors in many reproductive processes in mammals, such as luteolysis, fertilization, maternal recognition of pregnancy, and implantation (5). It has been previously demonstrated that PG are produced by the CL in numerous species (25–30). Prostaglandin E₂ is known as a luteotropic factor (1, 31, 32). Our preliminary *in vitro* study confirmed that PGE₂ plays a luteotropic role as an auto-paracrine factor stimulating P₄ production by equine luteal steroidogenic cells and CL tissues (33, 34). The effects of PGE₂ are mediated by four receptor subtypes, which are encoded by different genes: EP1, EP2, EP3, and EP4 (35). The expression of the EP2 and EP4 receptors in the uterus during the estrous cycle and pregnancy has been reported in mares (36). In contrast to PGE₂, PGF_{2α} is the main luteolytic agent secreted in pulses from the uterine endometrium of numerous mammals during luteolysis including mares (37–40). Ginther et al. (41) demonstrated that pulses of PGF_{2α} detected before the onset of luteolysis were less frequent per session and less prominent than during and after luteolysis.

According to our *in vitro* studies, in mare, many factors are involved in the secretion of PG from equine CL such as cytokine (42, 43) and from the endometrium such as P₄, E₂, oxytocin, LH, or cortisol (44–46) regulating modulating enzymatic cascade of AA metabolism. In the PG production cascade, prostaglandin-endoperoxide synthases (PTGS2) convert arachidonic acid (AA) into PGH₂. The conversion of PGH₂ into PGF_{2α} and PGE₂ is catalyzed by PGF_{2α} synthases (PTGFS) and PGE₂ synthases (PTGES), respectively. Prostaglandin H₂ is converted to PGI₂ by the action of PGI₂ synthases (PTGIS) (47). In addition, PGE₂ can be converted into PGF_{2α} through PGE₂-9-ketoreductase (PGE₂-9-K) activation, an enzyme which works also as 20-α-hydroxysteroid dehydrogenase (20α-HSD), converting P₄ into inactive 20-α-hydroxyprogesterone (20α-OHP) (4, 48). In mares, the aldo-keto reductase (AKR1C23), which has 20α-HSD activity, converting P₄ to its inactive metabolite, was expressed in the CL (30, 48) and placenta during placentitis (49). Moreover, 15-hydroxyprostaglandin dehydrogenase (PGDH), which is involved in the first step of PG inactivation, leading into the generation of 15-keto-metabolites, was expressed in mares in the CL (50), gravity uterus (51), and presented from 150 days of gestation onwards (52). Similar mechanisms that involved the activity of PGE₂-9-K were confirmed in the rabbit ovary (53, 54) and bovine placenta (55, 56). Therefore, due to the analysis of the action of PGE₂, its conversion into PGF_{2α} should also be considered. The above effect may depend on different interactions between luteotropic PGE₂ and luteolytic PGF_{2α}.


Many studies have discussed the benefits and disadvantages of different routes of PGE₂ administration and its proper dosages in mares (32, 57, 58). While some studies reported intrafollicular PGE₂ administration induced ovulation (58), in other studies intrauterine (intra-U) administration of PGE₂ resulted in prolonged CL (32). Moreover, the positive influence of intracervical administration of PGE₂ on the preparation of the uterine cervix to parturition in mares has been observed (59).

The area of research seeking the most effective routes and site for administration of luteotropic agents, used for manipulation of the reproductive processes in breeding mares, is still valuable for veterinary practitioners. To the best of our knowledge, no reports have demonstrated so far the action of PGE₂ on equine mid-luteal CL (day 10 of the estrous cycle) secretory function according to its application site. Therefore, the objective of this study was to determine the effects of PGE₂ on the secretory function of CL, according to the application site: ultrasound-guided intra-CL injection vs. intra-U administration. Moreover, the effect of intra-CL injection vs. intra-U administration of both luteotropic factors, PGE₂ and hCG (as a positive control), on CL function was additionally compared. Possibility of the conversion of luteotropic PGE₂ into luteolytic PGF_{2α} dependently on the dose was also examined.

MATERIALS AND METHODS

Animals and Surgical Procedures

Fifty-one clinically healthy, non-pregnant, and normally cycling mixed-breed mares (aged 3–13 years, weighing 400 ± 150 kg)



were used. The study was conducted between April and September 2016 in Poland. Mares were housed in private stables and were provided *ad libitum* access to water and fed hay and cereal grain. Horses deemed otherwise healthy based on a veterinary physical examination. Animal procedures were conducted in accordance with the EU Directive of the European Parliament and the Council on the protection of animals used for scientific purposes (22 September 2010; no 2010/63/EU), the Polish Parliament Act on Animal Protection (21 August 1997, Journal of Laws 1997 No 111 item 724) with further updates—the Polish Parliament Act on the protection of animals used for scientific or educational purposes (15 January 2015, Journal of Laws 2015 item 266). All animal procedures were designed to avoid or minimize discomfort, distress, and pain to the animals. Procedures were reviewed and accepted following the guidelines of the Local Ethics Committee for Experiments on Animals in Olsztyn, Poland (Approval No. 51/2011). Animals had no abnormalities of the reproductive tract detected by ultrasonic imaging. Prior to the experiment, mares received two doses of a PGF_{2α} analog (5 mg dinoprost, Dinolytic; Zoetis, Poland), 12

days apart, for synchronization of estrus. Follicular development was monitored in mares using transrectal palpation and USG at 12-h intervals during the periovulatory period until ovulation and every 2 days until day 10 (day 0 = day of ovulation). Moreover, structural changes of the CL during the entire estrous cycle were evaluated by ultrasonography with a 7.5-MHz linear probe (MyLabOne Vet Ultrasound System; ESOATE Pie Medica, Genoa, Italy), and visible signs of estrus (i.e., vaginal mucus and standing behavior) were assessed. In addition, the stage of the estrous cycle was confirmed by measurement of peripheral concentrations of P₄ in blood plasma samples collected from mares. **Figure 1** shows the *in vivo* study design where mares ($n = 51$) at day 10 of the estrous cycle were enrolled to the following experiments.

Intravenous Catheterization

Each mare was sedated with detomidine hydrochloride (Domosedan 0.01 mg/kg i.v.; Orion Pharma Poland Sp, Poland), followed by insertion of a temporary catheter (Intraflon IV cannulae 2.1 × 80 mm 14G, KRUSE, 121805; KRUSSE Poland)

into the jugular vein of mares. Intravenous catheters were flushed with heparinized saline and used for frequent blood sample collections.

An Intra-CL Injection

Caudal epidural anesthesia was achieved with 4 ml procaine hydrochloride (2% Polocainum Hydrochloricum; Biowet Drwalew, Poland). All intra-CL injections were administered under ultrasound guidance (7.5 MHz linear array transducer, MyLab 30 VET Gold Color Doppler Diagnostic Ultrasound System; ESOATE Pie Medica) through a sterile 1.25 × 50 mm (2-in. 18-gauge) ovum pick-up disposable veterinary injection needle (Bovivet, Poznan, Poland). The transducer and needle guide were coated with a sterile lubricant (Medicum, Lodz, Poland), and positioned within the vagina. The convex transducer was placed in the vagina against the vaginal fornix ipsilateral to the target ovary. The needle was then passed through the vaginal wall, and intraluteal treatments, PGE₂ (PGE₂, P0409; Sigma-Aldrich, Saint Louis, Missouri, USA) or hCG (Chorulon; Intervet International B.V., The Netherlands) dissolved in sterile saline solution (1 ml), were injected directly into the CL.

Intrauterine (Intra-U) Administration

The luteotropic factors were administered directly into the uterine lumen of mares. The catheter was protected by a sanitary sheath that was broken immediately before the catheter passed through the opening of the cervix. Prostaglandin E₂ or hCG dissolved in sterile saline solution was infused into the uterine horn using a 5-ml sterile syringe.

Experimental Design

Experiment 1. Dose-Dependent Effect of Prostaglandin E₂ on CL Function, Compared With Human Chorionic Gonadotropin Action

Experiment 1 design is shown in **Figure 1A**. The dose-dependent effect of PGE₂ on blood plasma P₄ concentrations in mares on day 10 of the estrous cycle was determined as follows: (1) one intra-U saline administration (control group; *n* = 3); (2) one intra-U administration of PGE₂ (1 mg/5 ml, 2.5 mg/5 ml, 5 mg/5 ml, 20 mg/5 ml; *n* = 3/per dose); (3) one intra-U administration of hCG (positive control; 1,500 IU/5 ml, 3,000 IU/5 ml, 4,500 IU/5 ml; *n* = 3/per dose).

Moreover, the possibility of PGE₂ conversion into PGF_{2α}, dependently on the dose, was also examined. The concentration of total PGF_{2α} (PGF_{2α} plus its main metabolite 13,14-dihydro-15-keto-prostaglandin F_{2α} – PGFM) in blood plasma of mares on day 10 of the estrous cycle was determined after different doses of PGE₂ application (**Table 2**). In mares, PGF_{2α} in the uterine vein reaches systemic circulation and is metabolized in the lungs much via PGDH, resulting in lower concentrations of PGF_{2α} (38, 60). The half-life of PGF_{2α} in mares is short (94 s); therefore, plasma concentrations of PGFM are used to represent changes in PGF_{2α} output (38, 60). The blood sampling was described in Blood Sampling section.

Experiment 2. The Comparison of Intra-CL Versus Intra-U Application Site of Prostaglandin E₂ on CL Function, Compared With Human Chorionic Gonadotropin Action

Experiment 2 design is shown in **Figure 1B**. To investigate the effect of PGE₂ according to the application site on the function of equine CL, mares on day 10 of the estrous cycle were managed as follows: (1) an intra-CL saline injection (control; *n* = 6); (2) one intra-CL injection of PGE₂ (5 mg/ml; *n* = 6); (3) an intra-CL injection of hCG (1,500 IU/ml; *n* = 6); (4) one intra-U saline administration (control; *n* = 6); (5) one intra-U administration of PGE₂ (5 mg/5 ml; *n* = 6); (6) one intra-U administration of hCG (1,500 IU/5 ml; *n* = 6). Mares (from experiment 1) with intra-U administrations of saline (*n* = 3), PGE₂ (5 mg/5 ml *n* = 3), and hCG (1,500 IU/5 ml; *n* = 3) were used in experiment 2, respectively. The blood sampling is described in Blood Sampling section.

Blood Sampling

In mares, blood was aspirated frequently from the jugular vein according to the schedule: at –2, –1, and 0 (pre-treatment), and at 1, 2, 3, 4, 6, 8, 10, 12, and 24 h after injection/administration as shown in **Figures 1A,B**. The time point of intra-CL injection or intra-U administration of PGE₂, hCG or saline was defined as hour “0” of the experiment. Blood was aspirated into sterile 10-ml tubes containing 100 μl of 0.3 M EDTA and 1% acetylsalicylic acid, pH 7.4. After centrifugation (2,000 × *g* for 10 min at 4°C), plasma was stored at –20°C for determination of P₄, PGE₂, PGF_{2α}, and PGFM concentrations.

Hormone Determination

Progesterone concentration in blood plasma was measured in duplicates via RIA (P4125 104 I” RIA kit, Immunotech, Czech Republic, IM1188), according to the manufacturer’s instructions. The standard curve for P₄ ranged from 0.1 to 100 ng/ml. The intra- and inter-assay coefficients of variation (CV) were 6.5 and 8.6%, respectively.

Prostaglandin E₂ was determined in blood samples using commercial ELISA kit (Enzyme Immunoassay kit; Enzo Life Science, Farmingdale, New York, USA, #ADI-901-001), according to the manufacturer’s instructions. The standard curve for PGE₂ ranged from 39.1 to 2,500 pg/ml. The sensitivity of the PGE₂ assay was 13.4 pg/ml. The cross-reactivity for various prostaglandins and their metabolites was as follows: PGE₂ 100%, PGE₁ 70%, PGE₃ 16.3%, PGF_{1α} 1.4%, PGF_{2α} 0.7%, and 6-keto-PGF_{1α} 0.6%. The intra- and inter-assay CV were 13.1% and 9.7%, respectively. The intra- and inter-assay CV were 5.8 and 5.1%, respectively.

13,14-Dihydro-15-keto-PGF_{2α} (PGFM) was determined in blood samples using a commercial ELISA kit (PGFM Enzyme Competitive ELISA Kit, Invitrogen, Thermo Fisher Scientific, #E1APGFM, UK), according to the manufacturer’s instructions. The standard curve for PGFM ranged from 50 to 3,200 pg/ml. The sensitivity of the PGFM assay was 20.8 pg/ml. The cross-reactivity for various prostaglandins and their metabolites was as follows: PGFM 100%, PGEM 1.5%, PGF_{2α} 0%, and PGE₂ 0%. The intra- and inter-assay CV were 7.5 and 9.6%, respectively.

TABLE 1 | The effect of one intrauterine administration of prostaglandin (PG) E₂ or human chorionic gonadotropin (hCG; positive control) on progesterone (P₄) concentrations in mares' blood plasma samples ($n = 3$ per dose) at day 10 of the estrous cycle.

Group	Dose	Progesterone	
		Baseline (ng/ml)	Total amount (mean ± SEM)
Control	Saline	10.78	80.44 ± 5.12
PGE ₂	1 mg	10.31	79.31 ± 22.10
	2.5 mg	10.21	68.6 ± 37.52
	5 mg	11.59	115.00 ± 8.99*
	20 mg	12.29	38.36 ± 50.91
hCG (positive control)	1,500 IU	11.67	115.2 ± 10.17*
	3,000 IU	10.91	81.81 ± 52.74
	4,500 IU	12.91	31.76 ± 16.84

All values are expressed as total amount of P₄ secretion (area under curve). Baseline indicates average concentration of P₄ (ng/ml) in the period before treatment (pre-treatment time: -2 to 0 h). Asterisks indicate significant differences in P₄ concentrations in PGE₂- or hCG-treated group versus control group. The results were considered significantly different at $p < 0.05$.

Prostaglandin F_{2α} was determined in blood samples using a commercial PGF_{2α} ELISA kit (ENZO Life Sciences Inc., Farmingdale, NY, USA; ADI-901-069) according to the manufacturer's instructions. The standard curve for PGF_{2α} ranged from 3.05 to 50,000 pg/ml. The sensitivity of the PGF_{2α} assay was 6.71 pg/ml. The cross-reactivity for various prostaglandins and their metabolites was as follows: PGF_{2α} 100%, PGF_{1α} 11.82%, PGD₂ 3.62%, 6-keto-PGF_{1α} 1.38%, PGI₂ 1.25%, and PGE₂ 0.77%. The intra- and inter-assay CV were 6.8 and 9.7%, respectively.

Statistical Analysis

For each statistical analysis, a Gaussian distribution was tested using D'Agostino and Pearson normality test (GraphPad Software version 8.3.0; GraphPad, San Diego, CA, USA). Parametric analyses were performed because normal distribution was assumed. Two-way ANOVA (GraphPad) test was used in experiment 1 (Supplementary Tables 1–3) and in experiment 2 (Supplementary Tables 4, 5). The results were considered significantly different at $p < 0.05$.

In experiment 1, the differences in P₄ concentrations in blood plasma samples between groups treated with different doses of PGE₂ or hCG and control group were measured as the area under the curve (AUC), using the total amount of P₄ concentrations (mean ± SEM) secreted during the experiments (Table 1). The differences in concentrations of P₄ (Figure 2), and total PGF_{2α} concentrations (Table 2) in blood plasma samples in response to treatment with different doses of PGE₂ or hCG were analyzed using a repeated measures design approach in which treatments and time of sample collection (h) were fixed effects and all interactions were included (two-way ANOVA test followed by Dunnett's multiple comparison test).

In experiment 2, data were analyzed by two-way ANOVA (treatments vs. the differences in P₄ and PGE₂ concentrations)

(Figures 3, 4) and blood plasma samples collected after application of PGE₂ or hCG were analyzed using a repeated measures design approach in which treatments and time of sample collection (h) were fixed effects and all interactions were included (two-way ANOVA test followed by Dunnett's multiple comparison test). All values are presented as percentage of the control. The differences in P₄ (Table 3) and PGE₂ (Table 4) concentrations in blood plasma samples between PGE₂ or hCG groups were measured as AUC, using the total amount of P₄ or PGE₂ concentrations secreted during the experiments and were calculated using two-way ANOVA, followed by Dunnett's multiple comparisons test.

RESULTS

Experiment 1. Dose-Dependent Effect of Prostaglandin E₂ on CL, Compared With Human Chorionic Gonadotropin Action

In mares, only one intra-U administration of PGE₂ at the dose of 5 mg/5 ml increased the total amount of P₄ concentrations in blood plasma, compared with the control group ($p < 0.05$; Table 1). An increase in P₄ concentrations was observed at 4 h and between 8 and 24 h after intra-U administration of PGE₂ at the dose of 5 mg/5 ml, compared with the control group and to its concentrations in the period before treatment (pre-treatment time) ($p < 0.05$; Figure 2A).

An increase in P₄ concentrations in blood plasma was observed at 2 h and between 4 h and 6 h after intra-U administration of PGE₂ at the dose of 1 mg/5 ml, compared with the control group ($p < 0.05$; Figure 2A), while intra-U administration of PGE₂ at the dose of 20 mg/5 ml decreased its concentrations at 6 h compared with the pre-treatment time, and at 8 h, compared with the control group ($p < 0.05$; Figure 2A).

The total amount of P₄ concentrations increased in blood plasma only after one intra-U administration of hCG at the dose of 1,500 IU/5 ml, compared with the control group ($p < 0.05$; Table 1). An increase in P₄ concentrations was observed at 1 h after one intra-U administration of hCG at the dose of 1,500 IU/5 ml compared with the control group ($p < 0.05$; Figure 2B). Moreover, an increase in P₄ concentrations was noticed at 1 h and between 10 and 12 h after intra-U hCG administration at the dose of 1,500 IU/5 ml, compared with its concentrations in the pre-treatment time ($p < 0.05$; Figure 2B).

An intra-U administration of hCG at the dose of 4,500 IU/5 ml decreased P₄ concentrations at 24 h, compared with the control group ($p < 0.001$; Figure 2B).

Concentrations of PGF_{2α} and its metabolite PGFM (total PGF_{2α}) in blood plasma samples increased at 1 h after an intra-U administration of PGE₂ at the dose of 2.5 mg/5 ml, compared with its concentrations in the pre-treatment time ($p < 0.05$; Table 2). Moreover, an increase in total PGF_{2α} concentrations was observed between 1 and 3 h after an intra-U administration of PGE₂ at the dose of 20 mg/5 ml, compared with its concentrations in the pre-treatment time ($p < 0.05$; Table 2).




FIGURE 2 | Concentration of progesterone (P₄) in the jugular vein blood plasma in mares with one intrauterine administration of **(A)** four different doses of prostaglandin (PG) E₂ (PGE₂; 1, 2.5, 5, 20 mg/5 ml, *n* = 3/dose) and **(B)** three different doses of human chorionic gonadotropin (hCG; positive control; 1,500, 3,000, 4,500 IU/5 ml, *n* = 3/dose) on day 10 of the estrous cycle, compared with control groups. All values are presented as % of the control. Different superscript letters ^{a,b,c} indicate significant differences in P₄ concentrations between PGE₂- or hCG-treated group vs. control group at specific time points of blood sample collection. Asterisks indicate significant differences between P₄ levels in PGE₂- or hCG-treated group vs. average concentration of P₄ in blood plasma in the period before treatment (pre-treatment time: -2 to 0 h). The results were considered significantly different at *p* < 0.05.

Experiment 2. Comparison of Intra-CL vs. Intra-U Application of Prostaglandin E₂ on Corpus Luteum Function, Compared With Human Chorionic Gonadotropin Action

An increase in P₄ concentrations in blood plasma samples was noticed in mares, between 3 and 4 h after receiving one intra-CL injection of PGE₂, compared with its concentrations in the pre-treatment time within PGE₂-treated group (*p* < 0.01), and with respect to the control mares (*p* < 0.01; **Figure 3A**). At the same time, P₄ concentrations increased between 8 and 24 h after intra-U administration of PGE₂, compared with P₄ concentrations in the pre-treatment time within PGE₂-treated group (*p* < 0.001), as well as compared with the control mares (*p* < 0.05; **Figure 3B**).

In mares, an intra-CL injection of hCG elevated P₄ levels at 6 h, compared with P₄ levels in the pre-treatment time within PGE₂-treated group (*p* < 0.05; **Figure 3A**). Moreover, one intra-CL injection of hCG (positive control) increased P₄ concentrations in blood plasma at 1, 6, and 12 h after its application, compared with the control group (*p* < 0.001; **Figure 3A**), while its intra-U administration elevated P₄ concentrations between 1 and 12 h, compared with the control group, and to P₄ concentrations in the pre-treatment time within this group of mares (*p* < 0.05; **Figure 3B**). Total amount of P₄ found in mares with intra-U administration of hCG was greater compared with total amount of P₄ in mares with its intra-CL injection (*p* < 0.05; **Table 3**).

TABLE 2 | The effect of one intrauterine administration of prostaglandin (PG) E₂ on total prostaglandin F_{2α} (the sum of PGF_{2α} and PGF_{2α} metabolite 13,14-dihydro-15-keto PGF_{2α}-PGFM) concentrations in mares' blood plasma samples (*n* = 3 per dose) at day 10 of the estrous cycle.

Time (h)	Total prostaglandin F _{2α} (pg/ml)				
	Saline (control)	Intra-U administration			
		1 mg PGE ₂	2.5 mg PGE ₂	5 mg PGE ₂	20 mg PGE ₂
-2	67.37 ± 10.57 ^a	73.90 ± 13.79 ^a	56.10 ± 1.56 ^a	70.43 ± 13.03 ^a	65.58 ± 2.57 ^a
-1	82.19 ± 11.06 ^a	89.00 ± 11.48 ^a	70.48 ± 1.28 ^a	89.48 ± 16.55 ^a	79.96 ± 3.11 ^a
0	92.00 ± 10.95 ^a	96.10 ± 12.75 ^a	68.48 ± 1.47 ^a	92.53 ± 11.21 ^a	80.01 ± 4.49 ^a
1	88.64 ± 4.10 ^a	102.59 ± 20.81 ^a	138.47 ± 4.77 ^b	86.91 ± 7.11 ^a	161.11 ± 9.80 ^b
2	76.62 ± 9.17 ^a	74.10 ± 16.01 ^a	51.75 ± 4.05 ^a	74.66 ± 9.13 ^a	109.39 ± 2.54 ^b
3	101.21 ± 12.30 ^a	79.16 ± 15.88 ^a	68.21 ± 0.03 ^a	73.25 ± 3.49 ^a	133.30 ± 2.37 ^b
4	84.06 ± 10.82 ^a	59.50 ± 6.79 ^a	57.88 ± 1.88 ^a	62.08 ± 3.51 ^a	73.45 ± 15.62 ^a
6	61.84 ± 1.72 ^a	84.92 ± 21.59 ^a	73.89 ± 7.98 ^a	57.93 ± 5.57 ^a	65.57 ± 11.33 ^a
8	127.73 ± 18.13 ^a	67.26 ± 10.59 ^a	86.80 ± 4.19 ^a	85.94 ± 10.57 ^a	76.49 ± 5.73 ^a
10	96.13 ± 9.48 ^a	65.37 ± 22.81 ^a	57.63 ± 7.52 ^a	58.96 ± 2.61 ^a	89.50 ± 1.14 ^a
12	64.18 ± 5.39 ^a	93.44 ± 14.36 ^a	79.25 ± 15.41 ^a	77.94 ± 16.17 ^a	64.58 ± 12.66 ^a
24	58.29 ± 5.94 ^a	71.36 ± 18.76 ^a	80.52 ± 26.61 ^a	70.45 ± 4.88 ^a	63.70 ± 6.16 ^a

All values are expressed as the mean ± SEM. Different superscript letters ^{a,b} within the column indicate significant differences in total PGF_{2α} concentrations in PGE₂-treated group versus the period before treatment (pre-treatment time: -2 to 0 h). The results were considered significantly different at *p* < 0.05.

In mares, an intra-CL injection of PGE₂ increased PGE₂ concentrations in blood plasma at 3 and 12 h after its administration, compared with the control group (*p* < 0.05; **Figure 4A**), while an intra-CL injection of hCG (positive control) increased its concentrations at 10 h after injection, compared with the control group (*p* < 0.05; **Figure 4A**). Prostaglandin E₂ concentrations were elevated after intra-U administration of PGE₂ at 1 h and between 3 and 4 h, relative to the control mares (*p* < 0.001), and to PGE₂ levels in the pre-treatment time (*p* < 0.05; **Figure 4B**). Moreover, intra-U administration of hCG (positive control) increased PGE₂ concentrations at 3 h and between 6 and 10 h after its administration, compared with the control group (*p* < 0.01; **Figure 4B**), and at 3 and 8 h after hCG administration, compared with PGE₂ levels in the pre-treatment time (*p* < 0.01; **Figure 4B**). No differences in the total amount of PGE₂ were observed between mares with intra-U administration and intra-CL injection (*p* > 0.05; **Table 4**).

DISCUSSION

Until now, many studies have been focusing on the different application route or sites of luteolytic/luteotropic factors that may be used in veterinary practices to regulate the estrous cycle in mares. In the literature, different ways of PGE₂ or hCG administrations have been demonstrated, for example, i.m., i.v., s.c., intrafollicular, or intracervical (10, 14, 17, 18, 58, 59). The ultrasound-guided intra-CL injection as a method for studying the direct effect of PGF_{2α} on reproductive function in mares was evaluated by Weber et al. (61). However, this technique is not widely known by practitioners. While intra-U administration of luteotropic PGE₂ on the CL function was described by Vanderwall et al. (32), in our study we demonstrated the effect of luteotropic factor PGE₂ on P₄ secretion, depending on the application site: intra-CL vs. intra-U in mares at day

10 of the estrous cycle. To the best of our knowledge, for the first time, we have showed that application of PGE₂ supports equine CL secretory function, regardless of the application site, consequently leading to differences in both P₄ and PGE₂ concentrations in blood plasma.

The role of PGE₂ on equine CL function is not fully understood. A previous *in vitro* study in cows confirmed that PGE₂ participates in luteoprotective mechanisms required for CL formation and maintenance (62), and stimulates the P₄ production by luteal steroidogenic cells (63). Moreover, in cows and ewes, there have been evidences that PGE₁ or PGE₂ prevented P₄-induced premature luteolysis by suppressing the loss of luteal LH receptors (64, 65).

Interestingly, our study shows that the action of PGE₂ on CL secretory function is determined by the application site and dose. An intra-CL injection of PGE₂ increased P₄ concentrations in blood plasma of mares at day 10 of the estrous cycle compared with the control group, suggesting its direct action. The aforementioned data are in agreement with a preliminary study conducted by our group (33, 34), showing that in mares PGE₂ plays a luteotropic role as an auto-paracrine factor stimulating P₄ production by luteal steroidogenic cells and CL tissues *in vitro*. Some decades ago, Vanderwall et al. (32) reported that a single intra-U administration of PGE₂ was capable to maintain prolonged luteal function in the mare *in vivo*. In the experiment of Vanderwall et al. (32), non-pregnant mares were continuously infused with 0.24 mg of PGE₂, from day 10 to 16 postestrus, using an osmotic minipump surgically placed into the uterine lumen. In our study, intra-U administration of PGE₂ increased P₄ concentrations in blood plasma on day 10 of the estrous cycle in mares, compared with the control group. Simple comparison between data obtained in our study and in the study of Vanderwall et al. (32) cannot be made because of differences in methodology of PGE₂ application.




FIGURE 3 | Concentrations of progesterone (P₄) in the jugular vein blood plasma in mares with one (A) intra-CL injection of saline (control; gray bar), prostaglandin (PG) E₂ (PGE₂; 5 mg/ml; red line), or human chorionic gonadotropin (hCG, positive control; 1,500 IU/ml, blue line) or (B) one intrauterine administration of saline (control; gray bar), PGE₂ (5 mg/5 ml; red line), or hCG (positive control; 1,500 IU/5 ml, blue line) on day 10 of the estrous cycle. All values were presented as % of the control. Different superscript letters ^{a,b,c} indicate significant differences between blood P₄ level in PGE₂- or hCG-treated groups of mares vs. control group at specific time points of blood sample collection. Asterisks indicate significant differences in blood P₄ level within PGE₂- or hCG-treated group of mares vs. average concentration of P₄ in blood plasma in the period before treatment (pre-treatment time: -2 to 0 h). Average concentrations of P₄ in the blood plasma samples of control mares during the period before treatment (pre-treatment time) were (A) 10.92 ng/ml or (B) 11.15 ng/ml, respectively. The results were considered significantly different at *p* < 0.05.

We should take into account that in our study, whereas P₄ concentrations increased at 3–4 h after direct intra-CL injection of PGE₂, the positive effect of intra-U administration of PGE₂ on P₄ concentrations was observed between 8 and 24 h after treatment. We suppose that the aforementioned effect is a result of indirect action of PGE₂ on PGE₂ receptors in the uterus, involving the regulation of vasculature events and induction of other luteotropic factors engaged in luteal support, in the equine endometrium (e.g., growth factors, nitric oxide, and cytokines). Galvão et al. (42, 66) showed that cytokines interact with nitric oxide synthases and influence luteal angiogenesis in mares as angiogenic factors themselves can also modulate luteal secretory function. Previously, Otzen et al. (67) found that PGE₂ stimulates vascular endothelial growth factor (VEGF), which participates in the regeneration and expansion of the equine uterine blood vessel network. Moreover, VEGF has been reported to effectively

modulate luteal secretory function of equine CL (P₄ and PGE₂ production) (66).

In the first experiment, the dose of PGE₂ 5 mg/5 ml was chosen as an effective dose based on an increase in P₄ concentrations in blood samples after intra-U treatments in mares. We demonstrated that the highest dose of PGE₂ administered into the uterus does not affect P₄ concentrations in blood plasma. Therefore, we can suspect the possibility of the conversion of PGE₂ by the PGE₂-9-K into PGF_{2α}. It is known that PGE₂-9-K enzyme has also a 20 α-HSD activity, and in fact converts P₄ into 20α-OH-P₄, which may contribute to the decrease of P₄ induced by PGF_{2α} (4, 48). To check and confirm this fact, we examined the effect of an intra-U administration of different doses of PGE₂ on total PGF_{2α} (sum of PGF_{2α} and its main metabolite—PGFM) concentrations in blood plasma on day 10 of the estrous cycle in mares. Interestingly,




FIGURE 4 | Concentrations of prostaglandin (PG) E₂ in the jugular vein blood plasma in mares with one **(A)** intra-CL injection of saline (control; gray bar), PGE₂ (5 mg/ml; red line), or human chorionic gonadotropin (hCG, positive control; 1,500 IU/ml, blue line) or **(B)** one intrauterine administration of saline (control; gray bar), PGE₂ (5 mg/5 ml; red line), or hCG (positive control; 1,500 IU/5ml, blue line) on day 10 of the estrous cycle. All values are presented as % of the control. Different superscript letters ^{a,b,c} indicate significant differences between blood PGE₂ level in PGE₂- or hCG-treated groups of mares vs. control group at specific time points of blood sample collection. Asterisks indicate significant differences in blood PGE₂ level within PGE₂- or hCG-treated group of mares vs. average concentration of PGE₂ in the period before treatment (pre-treatment time: -2 to 0 h). Average concentrations of PGE₂ in the blood plasma samples of control mares during the period before treatment (pre-treatment time) were **(A)** 243.39 ng/ml or **(B)** 264.18, respectively. The results were considered significantly different at *p* < 0.05.

TABLE 3 | The effect of one intra-CL injection or one intrauterine administration of prostaglandin (PG) E₂ or human chorionic gonadotropin (hCG; positive control) on progesterone (P₄) concentrations in mares' blood plasma samples (*n* = 6 per group) at day 10 of the estrous cycle.

Group	Type of administration	Progesterone
		Total amount (mean ± SEM)
PGE ₂	Intra-CL	13.55 ± 5.98 ^a
5 mg	Intra-U	28.19 ± 6.05 ^{ab}
hCG (positive control)	Intra-CL	23.25 ± 3.8 ^a
1,500 IU	Intra-U	49.24 ± 7.47 ^b

All values are expressed as total amount of P₄ secretion (area under curve). Different superscript letters ^{a,b} indicate significant differences in P₄ concentrations between PGE₂ and hCG groups. The results were considered significantly different at *p* < 0.05.

TABLE 4 | The effect of one intra-CL injection or one intrauterine administration of prostaglandin (PG) E₂ or human chorionic gonadotropin (hCG; positive control) on PGE₂ concentrations in mares' blood plasma samples (*n* = 6 per group) at day 10 of the estrous cycle.

Group	Type of administration	Prostaglandin E ₂
		Total amount (mean ± SEM)
PGE ₂	Intra-CL	408.9 ± 205.9 ^a
5 mg	Intra-U	994.8 ± 155.1 ^a
hCG (positive control)	Intra-CL	457.9 ± 132.4 ^a
1,500 IU	Intra-U	951.4 ± 176.7 ^a

All values are expressed as total amount of PGE₂ secretion (area under curve). Different superscript letters ^{a,b} indicate significant differences in PGE₂ concentration between PGE₂ and hCG groups. The results were considered significantly different at *p* < 0.05.

we observed higher total PGF_{2α} concentrations in blood plasma between 1 and 3 h after intra-U administration of PGE₂ at the highest dose (20 mg/5 ml), compared with its concentrations in

the pre-treatment time. Hence, our *in vivo* results should be interpreted carefully and our hypothesis that the lack of the effect of PGE₂ in the highest dose on P₄ concentrations may be related

to its conversion into PGF_{2α} by PGE2-9-K needs further studies in mares.

In our study, we assume that intra-CL injection and intra-U administration of PGE₂ increased its own concentration in blood plasma. There is evidence that in the endometrium of mare, PGF_{2α} has an auto-amplification system, stimulating its own production (40). Therefore, future study should be planned to assume whether there is a positive PGE₂ feedback loop and whether PGE₂ has a positive effect on its own production.

There are a large number of *in vivo* studies concerning the effect of hCG on CL function in mare (16–19, 68). Kelly et al. (18) and Watson et al. (19) demonstrated the positive luteotropic effect of hCG on P₄ secretion. Therefore, in our study, we decided to assign mares treated with intra-CL injection or intra-U administration of hCG as positive control group. In the present study, we observed an increase in P₄ concentration in blood plasma after intra-U administration of 1,500 IU of hCG. No effect on CL function was reported by Brito et al. (68), using one i.v. injection of this same dose—1,500 IU of hCG at day 10 after ovulation. In agreement with our results, a positive effect on P₄ secretion was observed in diestrus mares, using repeated i.m. injections of 1,000 IU of hCG (days 3, 4, 5) (18) or a single i.v. injection of 1,500 IU of hCG (day 8) (19). Interestingly, in our study one intra-U administration of hCG at the doses 3,000 IU or 4,500 IU did not affect P₄ secretion from equine CL. Likewise, Köhne et al. (16) did not observe any increase in P₄ concentration and luteal size after i.v. administration of 5,000 IU of hCG at day 5 after ovulation. Therefore, it might be suggested that higher doses of hCG are not related to their effectiveness. We have noted that both a single intra-CL injection of hCG and a single intra-U administration of hCG increased blood P₄ concentrations, supporting P₄ secretion from mare CL. The intra-CL injection of hCG seems to directly influence the luteal steroidogenic cells. An additional *in vitro* study should be conducted to explore molecular mechanisms involved in the CL secretory function in response to intra-CL injection of hCG. Unexpectedly, the intra-U administration of hCG was more effective in increasing P₄ secretion by CL (Table 3), throughout its indirect effect on equine PGE₂ receptors in the uterus, affecting regulation of vasculature events and induction of luteotropic factors involved in luteal support.

Human chorionic gonadotropin has structural and functional similarities with LH, sharing the same receptor with this luteotropic hormone (1). The evidence for the presence of the LH/CGR receptor in the reproductive tract of humans and other domestic animals is well described (11, 12). In mares, LH receptor expression occurs in the CL (69) and in the endometrium and myometrium during the estrous cycle and anestrus (13). Therefore, the presence of LH/CGR receptors in equine reproductive tract could mediate the indirect effect of intra-U administration of hCG and the direct effect of hCG injection into the CL. Interestingly, in the present study, we show that only one intra-U administration of hCG increases PGE₂ concentration in blood plasma. We have previously demonstrated that LH stimulated PGE₂ secretion by equine endometrium and myometrium (45). We postulate that hCG through LH/CGR receptors in the mare uterus affects the

luteotropic PGE₂ production. Moreover, PGE₂ has a positive effect on P₄ secretion. However, further studies are needed to clarify the mechanism of action of hCG on PGE₂ production within the equine reproductive tract.

In conclusion, the aforementioned results indicate the importance of proper application site of drugs and may influence drug delivery strategies in veterinary medicine. Application of PGE₂ supports equine CL function via augmentation of P₄ and PGE₂ secretions. Progesterone secretion in response to PGE₂ depends on their application site. In the present study, we found more effective increase in P₄ secretion after intra-U administration of luteotropic factors (especially hCG) than their intra-CL injections. Therefore, the efficacy of intra-CL site of application warrants further *in vitro* and *in vivo* studies. We confirm that therapeutic use of intra-U administration of luteotropic factors is an easily applicable, valuable method in veterinary practice that may be used to support early pregnancy in mares. However, this knowledge is still insufficient and needs better understanding of the endocrine, cellular, receptor, and molecular mechanism action of luteotropic factors on equine CL function.

DATA AVAILABILITY STATEMENT

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

ETHICS STATEMENT

The animal study was reviewed and approved by Local Ethics Committee for Experiments on Animals, University of Warmia and Mazury in Olsztyn, Poland (Approval No. 51/2011). Written informed consent was obtained from the owners for the participation of their animals in this study.

AUTHOR CONTRIBUTIONS

KKP-T: conceptualization, investigation, methodology, formal analysis, visualization, writing—original draft, and writing—review and editing. AWJ: investigation, methodology, formal analysis, visualization, writing—original draft, and writing—review and editing. AZS-M: conceptualization, investigation, methodology, formal analysis, writing—original draft, and writing—review and editing. EŻ: formal analysis. GF-D: supervision and writing—review and editing. DJS: conceptualization, investigation, formal analysis, supervision, funding acquisition, and writing—review and editing. All authors have read, critically revised, and approved the final version of the article.

FUNDING

This work was supported by the National Science Center in Poland (2011/02/A/NZ5/00338).

ACKNOWLEDGMENTS

The authors thank M. Szwichtenberg (Private horse stable Stajnia pod Klonem, Wiezyca, Poland) for his cooperation in providing animals for the study from the farm in Wiezyca. We are grateful to P. Warmowski (Private Veterinary Clinic Taurus, Kartuzy, Poland) for his veterinary assistance during the experiments. The authors wish to thank K. Jankowska, A. Baclawska, W. Krzywiec, and the Institute of Animal Reproduction and Food

Research, Polish Academy of Science, Olsztyn, Poland, for technical support in the experiments.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: <https://www.frontiersin.org/articles/10.3389/fvets.2021.753796/full#supplementary-material>

REFERENCES

- Niswender GD, Juengel JL, Silva PJ, Rollyson MK, McIntush EW. Mechanisms controlling the function and life span of the corpus luteum. *Physiol Rev.* (2000) 80:1–29. doi: 10.1152/physrev.2000.80.1.1
- Ginther OJ. Endocrinology of the ovulatory season. In: Ginther OJ, editor. *Reproductive Biology of the Mare*, 2nd edn. Wisconsin: Equiservices. (1992). p. 233–90.
- Pinto CRF. Impact of the corpus luteum on survival of the developing embryo and early pregnancy in mares. *Theriogenology.* (2020) 1:374–81. doi: 10.1016/j.theriogenology.2020.02.011
- Zerani M, Polisca A, Boiti C, Maranesi M. Current knowledge on the multifactorial regulation of corpora lutea lifespan: the rabbit model. *Animals.* (2021) 11:296. doi: 10.3390/ani11020296
- Weems CW, Weems YS, Randel RD. Prostaglandins and reproduction in female farm animals. *Vet J.* (2006) 171:206–28. doi: 10.1016/j.tvjl.2004.11.014
- Skarzynski DJ, Piotrowska-Tomala KK, Lukasz K, Galvão A, Farberov S, Zalman Y, et al. Growth and regression in bovine corpora lutea: regulation by local survival and death pathways. *Reprod Domest Anim.* (2013) 48:25–37. doi: 10.1111/rda.12203
- McCracken JA, Custer EE, Lamsa JC. Luteolysis: a neuroendocrine-mediated event. *Physiol Rev.* (1999) 79:263–323. doi: 10.1152/physrev.1999.79.2.263
- Masello M, Scarbolo M, Schneck MV, Perez MM, Schillkowsky EM, Sitko EM, et al. Intravaginal instillation of prostaglandin F_{2α} was as effective as intramuscular injection for induction of luteal regression in lactating dairy cows. *J Dairy Sci.* (2020) 103:2743–55. doi: 10.3168/jds.2019-17589
- Dordas-Perpinyà M, Normandin L, Dhier T, Terris H, Cochard A, Frilley C, et al. Single injection of triptorelin or buserelin acetate in saline solution induces ovulation in mares the same as a single injection of hCG. *Reprod Domest Anim.* (2020) 55:374–83. doi: 10.1111/rda.13632
- Morel MCGD, Newcombe JR. The efficacy of different hCG dose rates and the effect of hCG treatment on ovarian activity: ovulation, multiple ovulation, pregnancy, multiple pregnancy, synchrony of multiple ovulation in the mare. *Anim Reprod Sci.* (2008) 109:189–99. doi: 10.1016/j.anireprosci.2007.10.005
- Fields MJ, Shemesh M. Extragonadal luteinizing hormone receptors in the reproductive tract of domestic animals. *Biol Reprod.* (2004) 71:1412–8. doi: 10.1095/biolreprod.104.027201
- Cole LA. Biological functions of hCG and hCG-related molecules. *Reprod Biol Endocrinol.* (2010) 8:102–15. doi: 10.1186/1477-7827-8-102
- Esmeraldino AT, Malschitzky E, Fiala SM, Santarém L, Wolf CA, Jobim MIM, et al. Immunohistochemical identification of luteinizing hormone receptors in the extra-gonadal reproductive tract of the mare. *Anim Reprod Sci.* (2010) 121:38–9. doi: 10.1016/j.anireprosci.2010.04.132
- Kilicarslan MR, Horoz H, Senunver A, Konuk SC, Tek C, Carioglu B. Effect of GnRH and hCG on ovulation and pregnancy in mares. *Vet Rec.* (1996) 3:119–20. doi: 10.1136/vr.139.5.119
- Wilson CG, Downie CR, Hughes JP, Roser J. Effects of repeated hCG injections on reproductive efficiency in mares. *J Equine Vet Sci.* (1990) 10:301–8. doi: 10.1016/S0737-0806(06)80015-8
- Köhne M, Kuhl J, Ille N, Erber R, Aurich C. Treatment with human chorionic gonadotrophin before ovulation increases progesterin concentration in early equine pregnancies. *Anim Reprod Sci.* (2014) 149:187–93. doi: 10.1016/j.anireprosci.2014.07.002
- Alonso MA, Silva LA, Affonso FJ, Lemes KM, Celeghini ECC, Lançon R, et al. Effect of hCG application at different moments of the estrous cycle on corpus luteum and uterine vascularization and serum progesterone concentration in mares. *Anim Reprod.* (2019) 16:317–27. doi: 10.21451/1984-3143-AR2018-0103
- Kelly CM, Hoyer PB, Wise ME. *In-vitro* and *in-vivo* responsiveness of the corpus luteum of the mare and effect of hCG. *J Reprod Fertil.* (1988) 84:593–600. doi: 10.1530/jrf.0.0840593
- Watson ED, Colston M, Broadley C. LH and progesterone concentrations during diestrus in the mare and the effect of hCG. *Theriogenology.* (1995) 43:1325–37. doi: 10.1016/0093-691X(95)00117-Q
- Barbacini S, Zavaglia G, Gulden P, Marchi V, Necchi D. Retrospective study on the efficacy of hCG in an equine artificial insemination program using frozen semen. *Equine Vet Educ.* (2000) 12:312–7. doi: 10.1111/j.2042-3292.2000.tb00067.x
- Fricke PM, Reynolds LP, Redmer DA. Effect human chorionic gonadotropin administered early in the estrous cycle on ovulation and subsequent luteal function in cows. *J Anim Sci.* (1993) 71:1242–6. doi: 10.2527/1993.7151242x
- Breuel KF, Spitzer JC, Thompson CE, Breuel JF. First-service pregnancy rate in beef heifers as influenced by human chorionic gonadotropin administration before and/or after breeding. *Theriogenology.* (1990) 34:139–45. doi: 10.1016/0093-691X(90)90585-H
- Santos JE, Thatcher WW, Pool L, Overton MW. Effect of human chorionic gonadotropin on luteal function and reproductive performance of high-producing lactating Holstein dairy cows. *J Anim Sci.* (2001) 79:2881–94. doi: 10.2527/2001.79112881x
- Nishigai M, Kamomae H, Tanaka T, Kaneda Y. Improvement of pregnancy rate in Japanese Black cows by administration of hCG to recipients of transferred frozen-thawed embryos. *Theriogenology.* (2002) 58:1597–606. doi: 10.1016/S0093-691X(02)01062-2
- Diaz FJ, Anderson LE, Wu YL, Rabot A, Tsai SJ, Wiltbank MC. Regulation of progesterone and prostaglandin F_{2α} production in the CL. *Mol. Cell Endocrinol.* (2002) 191:65–80. doi: 10.1016/S0303-7207(02)00056-4
- Aroshi JA, Banu SK, Chapdelaine P, Madore E, Sirois J, Fortier MA. Prostaglandin biosynthesis, transport, and signaling in corpus luteum: a basis for autoregulation of luteal function. *Endocrinology.* (2004) 145:2551–60. doi: 10.1210/en.2003-1607
- Zerani M, Dall'Aglio C, Maranesi M, Gobetti A, Brecchia G, Mercati, et al. Intraluteal regulation of prostaglandin F_{2α}-induced prostaglandin biosynthesis in pseudopregnant rabbits. *Reproduction.* (2007) 133:1005–116. doi: 10.1530/REP-06-0107
- Skarzynski DJ, Siemieniuch MJ, Pilawski W, Woclawek-Potocka I, Bah MM, Majewska M, et al. *In vitro* assessment of progesterone and prostaglandin e(2) production by the corpus luteum in cattle following pharmacological synchronization of estrus. *J Reprod Dev.* (2009) 55:170–6. doi: 10.1262/jrd.20121
- Parillo F., Catone G, Maranesi M, Gobetti A, Gasparrini B, Russo, et al. Immunolocalization, gene expression, and enzymatic activity of cyclooxygenases, prostaglandin E₂-9-ketoreductase, and nitric oxide synthases in Mediterranean buffalo (*Bubalus bubalis*) corpora lutea during diestrus. *Microsc Res Tech.* (2012) 75:1682–90. doi: 10.1002/jemt.22116
- Kozai K, Hojo T, Tokuyama S, Szóstek AZ, Takahashi M, Sakatani M. Expression of aldo-keto reductase 1C23 in the equine corpus

- luteum in different luteal phases. *J Reprod Dev.* (2014) 60:150–4. doi: 10.1262/jrd.2013-120
31. Zavy MT, Bazer FW, Sharp DC, Frank M, Thatcher WW. Uterine luminal prostaglandin F in cycling mares. *Prostaglandins.* (1978) 16:643–50. doi: 10.1016/0090-6980(78)90194-6
 32. Vanderwall DK, Woods GL, Weber JA, Lichtenwalner AB. Corpus luteal function in nonpregnant mares following intrauterine administration of prostaglandin E(2) or estradiol-17 β . *Theriogenology.* (1994) 42:1069–83. doi: 10.1016/0093-691X(94)90855-9
 33. Lukasik K, Gola B, Galvao AM, Ferreira-Dias GM, Skarzynski DJ. Effect of prostaglandin E2 and F2 α on progesterone production of equine corpus luteum cells. In: *Reproduction in Domestic Animal 45. 14th Annual Conference of the European Society for Domestic Animal Reproduction.* Eger (2010).
 34. Lukasik K, Szóstek A, Galvao A, Hojo T, Okuda K, Skarzynski DJ. Auto-paracrine action of prostaglandins E2 and F2 α in equine corpus luteum. *J Equine Vet Sci.* (2014) 34:120. doi: 10.1016/j.jevs.2013.10.081
 35. Narumiya S, Sugimoto Y, Ushikubi F. Prostanoid receptors: structures, properties, and function. *Physiol Rev.* (1999) 79:1193–226. doi: 10.1152/physrev.1999.79.4.1193
 36. Silva ESM, Scoggin KE, Canisso IF, Troedsson MHT, Squires EL, Ball BA. Expression of receptors for ovarian steroids and prostaglandin E2 in the endometrium and myometrium of mares during estrus, diestrus and early pregnancy. *Anim Reprod Sci.* (2014) 30:169–81. doi: 10.1016/j.anireprosci.2014.11.001
 37. Lytton FD, Poyser NL. Prostaglandin production by the rabbit uterus and placenta *in vitro*. *J Reprod Fertil.* (1982) 66:591–9. doi: 10.1530/jrf.0.0660591
 38. Ginther OJ, Beg MA. The hour of transition into luteolysis in horses and cattle: a species comparison. *Theriogenology.* (2012) 77:1731–40. doi: 10.1016/j.theriogenology.2012.01.001
 39. Ginther OJ, Beg MA. Dynamics of circulating progesterone concentrations before and during luteolysis: a comparison between cattle and horses. *Biol Reprod.* (2012) 86:170, 1–12. doi: 10.1095/biolreprod.112.099820
 40. Kozai K, Tokuyama S, Szóstek AZ, Toishi Y, Tsunoda N, Taya K, et al. Evidence for a PGF2 α auto-amplification system in the endometrium in mares. *Reproduction.* (2016) 151:517–26. doi: 10.1530/REP-15-0617
 41. Ginther OJ, Rodrigues BL, Ferreira JC, Araujo RR, Beg MA. Characterisation of pulses of 13,14-dihydro-15-keto-PGF2 alpha (PGFM) and relationships between PGFM pulses and luteal blood flow before, during, and after luteolysis in mares. *Reprod Fertil Dev.* (2008) 20:684–93. doi: 10.1071/RD08077
 42. Galvão AM, Szóstek AZ, Skarzynski DJ, Ferreira-Dias GM. Role of tumor necrosis factor- α , interferon- γ and Fas-ligand on *in vitro* nitric oxide activity in the corpus luteum. *Cytokine.* (2013) 64:18–21. doi: 10.1016/j.cyto.2013.07.015
 43. Galvão AM, Ferreira-Dias GM, Chelmonska-Soyta A, Wocławek-Potocka I, Skarzynski DJ. Immune-endocrine cross-talk in reproductive biology and pathology. *Mediators Inflamm.* (2014) 2014:856465. doi: 10.1155/2014/856465
 44. Szóstek AZ, Galvão AM, Ferreira-Dias GM, Skarzynski DJ. Ovarian steroids affect prostaglandin production in equine endometrial cells *in vitro*. *J Endocrinol.* (2014) 30:263–76. doi: 10.1530/JOE-13-0185
 45. Piotrowska-Tomala KK, Jonczyk AW, Skarzynski DJ, Szóstek-Mioduchowska AZ. Luteinizing hormone and ovarian steroids affect *in vitro* prostaglandin production in the equine myometrium and endometrium. *Theriogenology.* (2020) 153:1–8. doi: 10.1016/j.theriogenology.2020.04.039
 46. Szóstek-Mioduchowska AZ, Shiotani H, Yamamoto Y, Sadowska A, Wójtowicz A, Kozai K, et al. Effects of cortisol on prostaglandin F2 α secretion and expression of genes involved in the arachidonic acid metabolic pathway in equine endometrium- *in vitro* study. *Theriogenology.* (2021) 173:221–9. doi: 10.1016/j.theriogenology.2021.08.009
 47. Simmons DL, Botting RM, Hla T. Cyclooxygenase isozymes: the biology of prostaglandin synthesis and inhibition. *Pharmacol Rev.* (2004) 56:387–437. doi: 10.1124/pr.56.3.3
 48. Brown KA, Boerboom D, Bouchard N, Doré M, Lussier JG, Sirois J. Human chorionic gonadotropin-dependent induction of an equine aldo-keto reductase (AKR1C23) with 20 α -hydroxysteroid dehydrogenase activity during follicular luteinization *in vivo*. *J Mol Endocrinol.* (2006) 36:449–61. doi: 10.1677/jme.1.01987
 49. El-Sheikh Ali H, Legacki EL, Scoggin KE, Loux SC, Dini P, Esteller-Vico A. Steroid synthesis and metabolism in the equine placenta during placentitis. *Reproduction.* (2020) 159:289–302. doi: 10.1530/REP-19-0420
 50. Sayasith K, Bouchard N, Doré M, Sirois J. Cloning of equine prostaglandin dehydrogenase and its gonadotropin-dependent regulation in theca and mural granulosa cells of equine preovulatory follicles during the ovulatory process. *Reproduction.* (2007) 133:455–66. doi: 10.1530/REP-06-0210
 51. Ousey JC, Fowden AL. Prostaglandins and the regulation of parturition in mares. *Equine Vet J.* (2012) 44:140–8. doi: 10.1111/j.2042-3306.2011.00506.x
 52. Han X, Rossdale PD, Ousey JC, Holdstock NB, Allen WR, Silver M. Localisation of 15-hydroxy prostaglandin dehydrogenase (PGDH) and steroidogenic enzymes in the equine placenta. *Equine Vet J.* (1995) 27:334–9. doi: 10.1111/j.2042-3306.1995.tb04067.x
 53. Schlegel W, Daniels D, Krüger S. Partial purification of prostaglandin E2-9-ketoreductase and prostaglandin-15-hydroxydehydrogenase from ovarian tissues of rabbits. *Clin Physiol Biochem.* (1987) 5:336–42.
 54. Wintergalen N, Thole, HH., Galla HJ, Schlegel W. Prostaglandin-E2 9-reductase from corpus luteum of pseudopregnant rabbit is a member of the aldo-keto reductase superfamily featuring 20 alpha-hydroxysteroid dehydrogenase activity. *Eur J Biochem.* (1995) 15:264–70. doi: 10.1111/j.1432-1033.1995.264_c.x
 55. Kankofer M, Wierciński J, Zerbe H. Prostaglandin E(2) 9-keto reductase activity in bovine retained and not retained placenta. *Prostaglandins Leukot Essent Fatty Acids.* (2002) 66:413–7. doi: 10.1054/plef.2002.0367
 56. Kankofer M, Wierciński J. Prostaglandin E2 9-keto reductase from bovine term placenta. *Prostaglandins Leukot Essent Fatty Acids.* (1999) 61:29–32. doi: 10.1054/plef.1999.0069
 57. Gastal MO, Gastal EL, Torres CA, Ginther OJ. Effect of PGE2 on uterine contractility and tone in mares. *Theriogenology.* (1998) 50:989–99. doi: 10.1016/S0093-691X(98)00202-7
 58. Martínez-Bovi R, Cuervo-Arango J. Intrafollicular treatment with prostaglandins PGE2 and PGF2alpha inhibits the formation of luteinised unruptured follicles and restores normal ovulation in mares treated with flunixin-meglumine. *Equine Vet J.* (2016) 48:211–7. doi: 10.1111/evj.12396
 59. Witkowski M, Pawłowski K. Clinical observations on the course of oxytocin or prostaglandin E2/oxytocin-induced parturition in mares. *Pol J Vet Sci.* (2014) 17:347–51. doi: 10.2478/pjvs-2014-0047
 60. Shrestha HK, Beg MA, Burnette RR, Ginther OJ. Plasma clearance and half-life of prostaglandin F2alpha: a comparison between mares and heifers. *Biol Reprod.* (2012) 87:1–6. doi: 10.1095/biolreprod.112.100776
 61. Weber JA, Causey RC, Emmans EE. Induction of luteolysis in mares by ultrasound-guided intraluteal treatment with PGF2alpha. *Theriogenology.* (2001) 55:1769–76. doi: 10.1016/S0093-691X(01)00519-2
 62. Korzekwa A, Jaroszewski JJ, Bogacki M, Deptula KM, Maslanka TS, Acosta TJ, et al. Effects of prostaglandin F(2alpha) and nitric oxide on the secretory function of bovine luteal cells. *J Reprod Dev.* (2004) 50:411–7. doi: 10.1262/jrd.50.411
 63. Kotwica J, Skarzynski D, Mlynarczyk J, Rekawiecki R. Role of prostaglandin E2 in basal and noradrenaline-induced progesterone secretion by the bovine corpus luteum. *Prostaglandins Other Lipid Mediat.* (2003) 70:351–9. doi: 10.1016/S0090-6980(02)00149-1
 64. Weems YS, Bridges PJ, Jeoung M, Arreguin-Arevalo JA, Nett TM, Vann RC, et al. *In vivo* intra-luteal implants of prostaglandin (PG) E1 or E2 (PGE1, PGE2) prevent luteolysis in cows. II: mRNA for PGF2 α , EP1, EP2, EP3 (A-D), EP3A, EP3B, EP3C, EP3D, and EP4 prostanoid receptors in luteal tissue. *Prostaglandins Other Lipid Mediat.* (2012) 97:60–5. doi: 10.1016/j.prostaglandins.2011.11.006
 65. Weems YS, Raney A, Pang J, Uchima T, Lennon E, Johnson D, et al. Prostaglandin E1 or E2 (PGE1, PGE2) prevents premature luteolysis induced by progesterone given early in the estrous cycle in ewes. *Theriogenology.* (2013) 80:507–12. doi: 10.1016/j.theriogenology.2013.05.014
 66. Galvão A, Henriques S, Pestka D, Lukasik K, Skarzynski D, Mateus LM, et al. Equine luteal function regulation may depend on the interaction between cytokines and vascular endothelial growth factor: an *in vitro* study. *Biol Reprod.* (2012) 22:187. doi: 10.1095/biolreprod.111.097147
 67. Otzen H, Sieme H, Oldenhof H, Kassens A, Ertmer F, Rode K, et al. Equine endometrial vascular pattern changes during the estrous cycle examined

- by Narrow Band Imaging hysteroscopy. *Anim Reprod Sci.* (2016) 166:80–9. doi: 10.1016/j.anireprosci.2016.01.006
68. Brito LFC, Baldrighi JM, Wolf CA, Ginther OJ. Effect of GnRH and hCG on progesterone concentrations and ovarian and luteal blood flow in diestrous mares. *Anim Reprod Sci.* (2017) 176:64–9. doi: 10.1016/j.anireprosci.2016.11.010
69. Roser JF, Evans JW. Luteal luteinizing hormone receptors during the postovulatory period in the mare. *Biol Reprod.* (1983) 29:499–510. doi: 10.1095/biolreprod29.2.499

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Piotrowska-Tomala, Jonczyk, Szóstek-Mioduchowska, Żebrowska, Ferreira-Dias and Skarzynski. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.